​

Blueprint Medicines (BPMC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BPMC Stock Forecast

Blueprint Medicines (BPMC) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $141.00, with a high of $150.00 and a low of $132.00. This represents a 9.98% increase from the last price of $128.21.

$85 $98 $111 $124 $137 $150 High: $150 Avg: $141 Low: $132 Last Closed Price: $128.21

BPMC Stock Rating

Blueprint Medicines stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 1 Strong Buy (3.33%), 18 Buy (60.00%), 11 Hold (36.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 30 11 18 1 Strong Sell Sell Hold Buy Strong Buy

BPMC Price Target Upside V Benchmarks

TypeNameUpside
StockBlueprint Medicines9.98%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts118
Avg Price Target$132.00$132.00$127.50
Last Closing Price$128.21$128.21$128.21
Upside/Downside2.96%2.96%-0.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 256951-21
May, 2551051-21
Apr, 2551151-22
Mar, 255951-20
Feb, 255951-20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2025Michael SchmidtGuggenheim$132.00$127.603.45%2.96%
Mar 07, 2025Scotiabank$150.00$87.1272.18%17.00%
Oct 31, 2024Ami FadiaNeedham$135.00$89.2451.28%5.30%
Oct 24, 2024David DaiUBS$88.00$84.404.27%-31.36%
Sep 19, 2024Bradley CaninoStifel Nicolaus$155.00$90.9470.44%20.90%
Aug 01, 2024Matthew BieglerOppenheimer$130.00$102.0527.39%1.40%
Jul 29, 2024Peter LawsonBarclays$105.00$112.19-6.41%-18.10%
Jul 08, 2024Matthew BieglerOppenheimer$125.00$116.557.25%-2.50%
May 06, 2024Andrew BerensLeerink Partners$97.00$107.19-9.51%-24.34%
May 03, 2024Christopher RaymondRaymond James$104.00$106.29-2.15%-18.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2025GuggenheimNeutraldowngrade
Jun 03, 2025CitigroupBuyMarket Performdowngrade
Jun 02, 2025Cowen & Co.Holddowngrade
Jun 02, 2025Wolfe ResearchPeer Performdowngrade
Jun 02, 2025ScotiabankOutperformSector Performdowngrade
Jun 02, 2025NeedhamBuyHolddowngrade
Jun 02, 2025WedbushMarket OutperformNeutraldowngrade
Mar 07, 2025ScotiabankOutperforminitialise
Nov 05, 2024CitigroupBuyBuyhold
Oct 31, 2024NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.76$-11.01$-9.35$-8.37$-1.07----
Avg Forecast$5.49$-6.27$-9.35$-8.58$-0.98$-0.88$1.80$4.23$6.00
High Forecast$6.80$-5.56$-8.07$-8.33$-0.76$0.21$5.79$8.72$6.65
Low Forecast$4.87$-7.77$-10.07$-8.80$-1.28$-1.80$-1.25$1.07$5.44
Surprise %4.92%75.60%--2.45%9.18%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$793.74M$180.08M$204.04M$249.38M$508.82M----
Avg Forecast$788.84M$176.15M$199.35M$245.11M$509.01M$725.96M$963.91M$1.21B$1.39B
High Forecast$933.98M$208.56M$211.25M$255.78M$522.14M$789.29M$964.17M$1.21B$1.51B
Low Forecast$719.96M$160.77M$178.49M$235.49M$503.40M$676.21M$963.64M$1.21B$1.29B
Surprise %0.62%2.23%2.35%1.74%-0.04%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$313.88M$-644.09M$-557.52M$-506.98M$-67.09M----
Avg Forecast$71.45M$-494.28M$-517.62M$-506.98M$-61.93M$-74.90M$103.91M$262.80M$363.24M
High Forecast$211.81M$-395.42M$-414.10M$-405.59M$-46.22M$12.79M$350.78M$528.05M$402.96M
Low Forecast$-68.91M$-593.13M$-621.15M$-608.38M$-77.65M$-108.71M$-75.65M$64.79M$329.55M
Surprise %339.30%30.31%7.71%-8.33%----

BPMC Forecast FAQ

Is Blueprint Medicines stock a buy?

Blueprint Medicines stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 18 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Blueprint Medicines is a favorable investment for most analysts.

What is Blueprint Medicines's price target?

Blueprint Medicines's price target, set by 30 Wall Street analysts, averages $141 over the next 12 months. The price target range spans from $132 at the low end to $150 at the high end, suggesting a potential 9.98% change from the previous closing price of $128.21.

How does Blueprint Medicines stock forecast compare to its benchmarks?

Blueprint Medicines's stock forecast shows a 9.98% upside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Blueprint Medicines over the past three months?

  • June 2025: 28.57% Strong Buy, 42.86% Buy, 23.81% Hold, 4.76% Sell, 0% Strong Sell.
  • May 2025: 23.81% Strong Buy, 47.62% Buy, 23.81% Hold, 4.76% Sell, 0% Strong Sell.
  • April 2025: 22.73% Strong Buy, 50.00% Buy, 22.73% Hold, 4.55% Sell, 0% Strong Sell.

What is Blueprint Medicines’s EPS forecast?

Blueprint Medicines's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.88, marking a -17.76% decrease from the reported $-1.07 in 2024. Estimates for the following years are $1.8 in 2026, $4.23 in 2027, and $6 in 2028.

What is Blueprint Medicines’s revenue forecast?

Blueprint Medicines's average annual revenue forecast for its fiscal year ending in December 2025 is $725.96M, reflecting a 42.67% increase from the reported $508.82M in 2024. The forecast for 2026 is $963.91M, followed by $1.21B for 2027, and $1.39B for 2028.

What is Blueprint Medicines’s net income forecast?

Blueprint Medicines's net income forecast for the fiscal year ending in December 2025 stands at $-74.901M, representing an 11.64% increase from the reported $-67.089M in 2024. Projections indicate $103.91M in 2026, $262.8M in 2027, and $363.24M in 2028.